Aerovate Therapeutics Stock Downgraded After Trial Setback
Aerovate Therapeutics Inc. experienced a significant change in its stock rating on Monday after BTIG downgraded the company's stock from Buy to Neutral. This change came about after a disappointing result from a key clinical trial for their drug candidate, AV-101.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
